Complement receptor 2 downregulation is associated with mortality in Staphylococcus aureus sepsis in both mice and humans
By
Pradeep Kumar Kopparapu
Meghshree Deshmukh
Santhilal Subhash
Majd Mohammad
Zhicheng Hu
Anders Jarneborn
Muhammad Arif
Marcela Pekna
Lars Ljungström
Gunnar Jacobsson
Ola Grimsholm
Tao Jin
July 9, 2026
Clinical Scorecard: Downregulation of Complement Receptor 2 Correlates with Increased Mortality in Staphylococcus aureus Sepsis in Mice and Humans
At a Glance
Category Detail
Condition Sepsis due to Staphylococcus aureus Key Mechanisms Downregulation of complement receptor 2 (CR2) correlates with increased mortality and reflects B-cell activation and immune dysregulation. Target Population Patients with severe invasive bacterial infections, particularly those caused by Staphylococcus aureus. Care Setting Clinical assessment and management of sepsis in hospital settings.
Key Highlights
CR2 downregulation is significantly associated with mortality in sepsis patients. B-cell depletion and CR2 downregulation correlate with disease severity in S. aureus infections. CR2 expression loss may indicate immune dysregulation during severe infections. Guideline-Based Recommendations
Diagnosis
Identify biomarkers such as CR2 for early risk stratification in sepsis. Management
Consider antibiotic treatment to restore CR2 expression in infected patients. Monitoring & Follow-up
Monitor CR2 levels as a potential indicator of disease severity and patient outcomes. Risks
Increased mortality associated with CR2 downregulation in sepsis. Patient & Prescribing Data
Patients with severe invasive bacterial infections, particularly those with Staphylococcus aureus sepsis.
Antibiotic treatment may reverse CR2 downregulation and improve outcomes.
Clinical Best Practices
Utilize CR2 as a candidate biomarker for monitoring immune responses in sepsis. Implement early therapeutic interventions based on biomarker assessments. Related Resources & Content
